Epygenix Therapeutics Inc.

Address: 630 West Germantown Pike Suite 215

Sponsor Overview

assignment

Specializations

Epilepsy in Rare Neurological Disorders

Epygenix Therapeutics Inc. focuses on clinical research in epileptic encephalopathies, with activity centered on Dravet syndrome and Lennox-Gastaut syndrome. These conditions reflect a therapeutic interest in severe, treatment-resistant seizure disorders affecting children and adults.

Dravet syndrome
Lennox-Gastaut syndrome
Seizure control
Rare pediatric neurology

The sponsor’s clinical program is aligned with neurological disease management in populations with complex and persistent seizure burden.

Antiseizure Therapeutics

Research activity includes evaluation of clemizole hydrochloride and EPX-100 in the context of adjunctive treatment for refractory epilepsy syndromes. The therapeutic focus is on agents intended to support seizure reduction in patients with limited treatment options.

Adjunctive therapy
Refractory seizures
Antiseizure agents
Therapeutic response in epilepsy

This area reflects interest in novel pharmacologic approaches for difficult-to-manage seizure disorders.

Child and Adult Neurology

The sponsor’s studies include both children and adult participants, indicating a cross-age clinical focus within severe epilepsy care. This supports investigation of treatments across different stages of life in syndromes that often begin early and persist long term.

Pediatric neurology
Adult epilepsy care
Long-term seizure disorders
Developmental epileptic encephalopathy

The clinical scope includes age-diverse patient populations affected by chronic neurological impairment linked to epilepsy.

Multicenter Rare Disease Research

Clinical operations extend across multiple research sites and countries, supporting studies in rare disease neurology with broad participant access. The sponsor’s work is concentrated on specialized epilepsy programs requiring coordinated clinical evaluation.

Multicenter clinical research
Rare disease trials
International site networks
Specialty epilepsy centers

This footprint is consistent with research in orphan neurological conditions where trial participation depends on distributed specialist sites.

Trial Name	Country	Status
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Clemizole Hydrochloride as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome	Czechia Hungary Italy Poland Romania Spain	Recruiting
Evaluation of Clemizole Hydrochloride (EPX-100) as Adjunctive Therapy in Pediatric and Adult Dravet Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial	Hungary Poland Spain	Recruiting